Global Diabetic Retinopathy Market 2015-2019

"01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.3 Product Profiles
03.3.1 Lucentis
03.3.2 Eylea
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Disease Overview
06.1 Understanding the Disease
06.2 Etiology
06.2.1 Elevated Blood Glucose
06.2.2 Ischemia
06.2.3 Hypoxia
06.2.4 Neovascularization
06.2.5 Increased Permeability of Retinal Vessels
06.3 Diagnosis
06.3.1 Retinal Photography
06.3.2 Fluorescein Angiography
06.3.3 Optical Coherence Tomography
06.4 Classification
06.4.1 Proliferative Diabetic Retinopathy
06.4.2 Non-proliferative Diabetic Retinopathy
06.5 Epidemiology
06.6 Management
06.6.1 Anti-VEGF Therapy
06.6.2 Intraocular Steroid Injection
06.6.3 Laser Surgery
06.6.4 Vitrectomy
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Key Takeaways
07.4 Five Forces Analysis
08. Pipeline Portfolio
09. Market Segmentation by Type of Molecule
09.1 Biologics
09.2 Corticosteroids
10. Market Segmentation by Route of Administration
10.1 Intravitreal
10.2 Intravenous
11. Geographical Segmentation
11.1 Diabetic Retinopathy Market in Americas
11.1.1 Market Size and Forecast
11.2 Diabetic Retinopathy Market in EMEA
11.2.1 Market Size and Forecast
11.3 Diabetic Retinopathy Market in APAC
11.3.1 Market Size and Forecast
12. Buying Criteria
13. Market Growth Drivers
14. Drivers and their Impact
15. Market Challenges
16. Impact of Drivers and Challenges
17. Market Trends
18. Trends and their Impact
19. Vendor Landscape
19.1 Competitive Scenario
19.1.1 Key News
19.1.2 Mergers and Acquisitions
19.2 Market Share Analysis 2014
19.2.1 Novartis
19.2.2 F. Hoffmann-La Roche
19.2.3 Regeneron Pharmaceuticals
19.2.4 Bayer
19.3 Other and Future Prominent Vendors
20. Key Vendor Analysis
20.1 Bayer
20.1.1 Key Facts
20.1.2 Business Overview
20.1.3 Business Segmentation by Revenue 2014
20.1.4 Business Segmentation by Revenue 2013 and 2014
20.1.5 Geographical Segmentation by Revenue 2014
20.1.6 Business Strategy
20.1.7 Recent Developments
20.1.8 SWOT Analysis
20.2 F. Hoffmann-La Roche
20.2.1 Key Facts
20.2.2 Business Overview
20.2.3 Business Segmentation
20.2.4 Business Segmentation by Revenue 2012 and 2013
20.2.5 Sales by Geography
20.2.6 Business Strategy
20.2.7 Key Information
20.2.8 SWOT Analysis
20.3 Novartis
20.3.1 Key Facts
20.3.2 Business Description
20.3.3 Business Segmentation
20.3.4 Revenue by Business Segmentation
20.3.5 Revenue Comparison 2012 and 2013
20.3.6 Sales by Geography
20.3.7 Business Strategy
20.3.8 Key Developments
20.3.9 SWOT Analysis
20.4 Regeneron Pharmaceuticals
20.4.1 Key Facts
20.4.2 Business Overview
20.4.3 Product Segmentation
20.4.4 Revenue Product Segmentation
20.4.5 Business Strategy
20.4.6 Key Information
20.4.7 SWOT Analysis
21. Other Reports in this Series